AWhat changed
CD19-directed engineered T cells showed a high response signal in a hard-to-treat ALL cohort.
Scientific scope
Exact 2014 nineteen-author cohort; later trials, licensure, manufacturing and long-term safety excluded.
Evidence
The linked sources identify this contribution and its scope. WRS has not independently reconstructed the scientific claims. The record is a small uncontrolled 2014 cohort with follow-up ranging from one to 24 months. It does not substitute for later multicentre trials, approvals, manufacturing evidence or long-term comparative safety.
Contributors
- The named authors listed in the linked research record · SCIENCE: Complete source byline retained in the research record; this collective display does not merge person identities or measure labor shares.
- Maude et al., Chimeric antigen receptor T cells for sustained remissions in leukemia
- Maude et al., Chimeric antigen receptor T cells for sustained remissions in leukemia
Provisional WRS assessment, edition 2026-10-16.1. Independent expert calibration is pending. This grade does not certify correctness or assign ownership.
Full scientific record · Browse contribution grades · Request a correction